Dataset Information

Zeilfelder2025 - Model for human liver cancer cell line HepG2

ABSTRACT: Mathematical multi-compartment model described by sets of coupled ordinary differential equations (ODEs) for studying the IL6 and SMAD signaling in HepG2 human cancer cell lines.

SUBMITTER: Nantia Leonidou

PROVIDER: MODEL2503270001 | BioModels | 2025-11-13

REPOSITORIES: BioModels

ACCESS DATA

Publications

Diclofenac and acetaminophen dim the acute-phase response but amplify expression of the iron regulator hepcidin in liver cancer cells.

Zeilfelder Anja A Vanlier Joep J Mölders Christina C Kastl Philipp P Helm Barbara B Burbano de Lara Sebastian S Möcklinghoff Till T Leonidou Nantia N Holstein Elisa E Vlasov Artyom A Held Alexander A Wilken Silvana S Hoffmann Katrin K Schicht Gerda G Scheffschick Andrea A Katerinopoulou Markella M Giehl-Brown Esther E Kahlert Christoph C Michalski Christoph C Seehofer Daniel D Damm Georg G Muckenthaler Martina U MU Schilling Marcel M Timmer Jens J Klingmüller Ursula U

Cell systems 20251110 11

Cancer patients frequently suffer from anemia and cancer-related pain, which can be treated by non-opioid analgesics such as diclofenac (DCF) and acetaminophen (APAP) attenuating inflammatory responses. The pro-inflammatory cytokine interleukin (IL)-6 triggers the expression of acute-phase proteins, including the iron regulator hepcidin. Using proteomics and dynamic pathway modeling, we show that DCF and APAP directly impact IL-6 signaling by enhancing the induction of the feedback-inhibitor sup ...[more]

PMID: 41218607

Similar Datasets

Project description:Hass2017-PanRTK model for single cell line The model structure comprises heterodimerization and receptor trafficking as described in detail in the article below. For ligand input, set a respective event. The illustrated event sets the EGF concentration to 2.5 nMol in the model file. This model is described in the article: Predicting ligand-dependent tumors from multi-dimensional signaling features. Hass H, Masson K, Wohlgemuth S, Paragas V, Allen JE, Sevecka M, Pace E, Timmer J, Stelling J, MacBeath G, Schoeberl B, Raue A. NPJ Syst Biol Appl 2017; 3: 27 Abstract: Targeted therapies have shown significant patient benefit in about 5-10% of solid tumors that are addicted to a single oncogene. Here, we explore the idea of ligand addiction as a driver of tumor growth. High ligand levels in tumors have been shown to be associated with impaired patient survival, but targeted therapies have not yet shown great benefit in unselected patient populations. Using an approach of applying Bagged Decision Trees (BDT) to high-dimensional signaling features derived from a computational model, we can predict ligand dependent proliferation across a set of 58 cell lines. This mechanistic, multi-pathway model that features receptor heterodimerization, was trained on seven cancer cell lines and can predict signaling across two independent cell lines by adjusting only the receptor expression levels for each cell line. Interestingly, for patient samples the predicted tumor growth response correlates with high growth factor expression in the tumor microenvironment, which argues for a co-evolution of both factors in vivo. This model is hosted on BioModels Database and identified by: MODEL1708210000. To cite BioModels Database, please use: Chelliah V et al. BioModels: ten-year anniversary. Nucl. Acids Res. 2015, 43(Database issue):D542-8. To the extent possible under law, all copyright and related or neighbouring rights to this encoded model have been dedicated to the public domain worldwide. Please refer to CC0 Public Domain Dedication for more information.

Dataset Information

Zeilfelder2025 - Model for human liver cancer cell line HepG2

Publications

Diclofenac and acetaminophen dim the acute-phase response but amplify expression of the iron regulator hepcidin in liver cancer cells.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets